CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
"This is a single-arm, open-label, multi-center study of complete molecular response (CMR) in
adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic
myelogenous leukemia in chronic phase (CML-CP). The study is designed to evaluate early and
deep molecular responses up to 4 years on nilotinib treatment. The primary end point is Rate
of confirmed CMR in newly diagnosed Philadelphia chromosome positive CML-CP patients."